Biotech Awards 2017

ghp Biotechnology Awards 2017 | 9 Full-Service Clinical Research Organization - Texas From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrolment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™. Yamin explains that Pharm-Olam works with drug development companies of all sizes, but they match best with small to mid-size pharmaceutical and biotechnology companies. “Pharm-Olam offers expertise in most therapeutic areas, however we have deep expertise in allergy, anti-infectives, and now, through the addition of some key staff, we are extending into immuno-oncology and biosimilars. We believe that we best serve our partners by not being influenced in our decisions by financial influences. “The CRO industry is extremely competitive and there are numerous companies that provide similar services, which means that it can be difficult to set ourselves apart. There has also been extensive change in the financial circumstances for CROs, which has included mergers, acquisitions, significant investments by private venture firms, and a few of the larger companies going public. “At Pharm-Olam, we set ourselves apart from our competitors in a number of ways. Firstly, we are a proven and stable partner; Pharm- Olam was founded in 1994, is privately owned, debt free and boasts a large and diverse client base and long history of success in obtaining marketing approvals for sponsors. Our experienced CRAs average over six years of monitoring experience and the majority of our clinical staff in emerging markets are physicians or PhDs. “We also lead the way in terms of technical efficiencies, as our data enhancements can integrate randomization into EDC systems, thus eliminating IVRS costs, with the added benefit of full inventory control over supplies. With offices and field staff in densely populated cities across emerging and traditional research markets, our access to large hospitals and patient pools results in less travel time and fewer associated costs throughout the study duration. It is also crucial that we remain transparent at all stages of the process, allowing us to take prompt action to keep timelines and budgets on track. “Pharm-Olam has a small company culture, with a flat organization structure. Pharm- Olam Senior management is atypical to other organizations in that they become involved with the onset of the proposal request, to the reward, internal handover and management of the ongoing clinical study.” Pharm-Olam International is a mid-size multinational Contract Research Organization (CRO), offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. We spoke to Yamin Khan to find out more about the service offering of the firm and how it sets itself apart in an increasingly competitive market. BI170008 Company: Pharm-Olam International Name: Yamin “Mo” Khan Email: [email protected] Web Address: Address: 450 N. Sam Houston Parkway E., Houston, TX 77060 Telephone: 713-779-5900